Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
T Cells and Myeloid Cells in Cancer Immunotherapy
share announcement

T Cells and Myeloid Cells in Cancer Immunotherapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 5739

Special Issue Editors

Dr. Byung-Gyu Kim

E-Mail Website
Guest Editor
Division of Pediatric Hematology-Oncology, Department of Pediatrics, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
Interests: TGF-beta signaling; T cells; inflammation-associated cancer; osteosarcoma; multiple myeloma; immunotherapy; drug resistance; predictive biomarker; combination strategy
Dr. David Askew

E-Mail Website
Guest Editor
Department of Pediatrics, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
Interests: myeloid-derived suppressor cells; graft-versus host disease; tumor associated macrophage; antigen processing; antigen presentation; pre-clinical tumor models; relapsing T cell leukemia

Special Issue Information

Dear Colleagues,

Cancer immunotherapy is essential for the treatment of solid tumors as well as blood cancers. Immune checkpoint inhibitors (ICI) represent a major breakthrough in the treatment of tumors. However, the majority of patients still do not respond to immunotherapy, including ICIs, soluble factors, and cell therapy, and develop a resistance to immunotherapy as well as to chemotherapy. 

CD4+ T cells play a key role not only in the maintenance of immune homeostasis in the physiologic and pathologic conditions, but also in the promotion or reduction of the efficiency of immunotherapy and chemotherapy. Therefore, a better understanding of the characteristics of CD4+ T cells helps improve the efficacy of cancer therapy, including personalized therapy, immunotherapy, chemotherapy and radiotherapy, as well as combination strategies.

This Special Issue highlights CD4+ T cells in current challenges and new potential approaches of cancer therapy in order to better rationalize immunotherapy strategies and overcome resistance.

Dr. Byung-Gyu Kim
Dr. David Askew
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • memory CD4+ T cell
  • regulatory T cell
  • cytotoxic CD4+ T cell
  • T-cell exhaustion
  • cytokine
  • immune checkpoint
  • immunotherapy
  • therapy resistance
  • predictive biomarker
  • combination strategy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 1353 KiB  
Article
Circulating Exhausted PD-1+CD39+ Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade
by Carlos Martinez-Gomez, Marie Michelas, Clara-Maria Scarlata, Anna Salvioni, Carlos Gomez-Roca, Victor Sarradin, Françoise Lauzéral-Vizcaino, Virginie Féliu, Agnès Dupret-Bories, Gwénaël Ferron, Jérôme Sarini, Christel Devaud, Jean-Pierre Delord, Camille-Charlotte Balança, Alejandra Martinez and Maha Ayyoub
Cancers 2022, 14(15), 3679; https://doi.org/10.3390/cancers14153679 - 28 Jul 2022
Cited by 6 | Viewed by 3007
Abstract
Tumor-infiltrating exhausted PD-1hiCD39+ tumor-antigen (Ag)-specific CD4 T cells contribute to the response to immune checkpoint blockade (ICB), but their circulating counterparts, which could represent accessible biomarkers, have not been assessed. Here, we analyzed circulating PD-1+CD39+ CD4 T [...] Read more.
Tumor-infiltrating exhausted PD-1hiCD39+ tumor-antigen (Ag)-specific CD4 T cells contribute to the response to immune checkpoint blockade (ICB), but their circulating counterparts, which could represent accessible biomarkers, have not been assessed. Here, we analyzed circulating PD-1+CD39+ CD4 T cells and show that this population was present at higher proportions in cancer patients than in healthy individuals and was enriched in activated HLA-DR+ and ICOS+ and proliferating KI67+ cells, indicative of their involvement in ongoing immune responses. Among memory CD4 T cells, this population contained the lowest proportions of cells producing effector cytokines, suggesting they were exhausted. In patients with HPV-induced malignancies, the PD-1+CD39+ population contained high proportions of HPV Ag-specific T cells. In patients treated by ICB for HPV-induced tumors, the proportion of circulating PD-1+CD39+ CD4 T cells was predictive of the clinical response. Our results identify CD39 expression as a surrogate marker of circulating helper tumor-Ag-specific CD4 T cells. Full article
(This article belongs to the Special Issue T Cells and Myeloid Cells in Cancer Immunotherapy)
►▼ Show Figures

Figure 1

Review

Jump to: Research

12 pages, 1120 KiB  
Review
Immune Regulation by Cytosolic DNA Sensors in the Tumor Microenvironment
by Keitaro Fukuda
Cancers 2023, 15(7), 2114; https://doi.org/10.3390/cancers15072114 - 1 Apr 2023
Cited by 2 | Viewed by 2261
Abstract
cGAS and AIM2 are CDSs that are activated in the presence of cytosolic dsDNA and are expressed in various cell types, including immune and tumor cells. The recognition of tumor-derived dsDNA by CDSs in the cytosol of tumor-infiltrating dendritic cells (TIDCs) activates the [...] Read more.
cGAS and AIM2 are CDSs that are activated in the presence of cytosolic dsDNA and are expressed in various cell types, including immune and tumor cells. The recognition of tumor-derived dsDNA by CDSs in the cytosol of tumor-infiltrating dendritic cells (TIDCs) activates the innate and acquired immunity, thereby enhancing anti-tumor immune responses. STING is the downstream signaling effector of cGAS that induces type I interferon (IFN) signaling. Owing to their ability to activate TIDCs, STING agonists have been intratumorally injected in several clinical trials to enhance the anti-tumor immune response elicited by immune checkpoint antibodies. However, they have shown minimal effect, suggesting the importance of optimizing the dose and route of administration for STING agonists and deciphering other immune pathways that contribute to anti-tumor immune responses. Recent studies have revealed that AIM2 activity induces pro-tumor growth through multiple parallel pathways, including inhibition of STING-type I IFN signaling. Thus, AIM2 could be a potential molecular target for cancer immunotherapies. This review summarizes the current research on the roles of cGAS, STING, and AIM2 in immune cells and tumor cells in the tumor microenvironment and discusses the future prospects of anti-tumor treatment approaches based on these molecules. Full article
(This article belongs to the Special Issue T Cells and Myeloid Cells in Cancer Immunotherapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop